Decreased Galectin-3 Expression in Prostate Cancer

Ronald A. Pacis,1 Mary Josephine Pilat,1 Kenneth J. Pienta,1,2* Avraham Raz,4 Victor Hogan,4 and Carlton R. Cooper1

1University of Michigan Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Internal Medicine, St. John’s Hospital, Detroit, Michigan
2Section of Urology, Department of Surgery, St. John’s Hospital, Detroit, Michigan
3Department of Pathology, St. John’s Hospital, Detroit, Michigan
4Karmanos Cancer Institute and Wayne State University, Detroit, Michigan

BACKGROUND. Galectin-3 is a carbohydrate-binding protein whose level of expression has been shown to be correlated with metastatic potential in a number of different tumor types. The purpose of this investigation was to examine galectin-3 expression in several tumorigenic and nontumorigenic prostate cell lines and prostate tissue samples.

METHODS. The expression of galectin-3 in cell lines and tissue samples was evaluated by tissue immunohistochemistry and Western blot analysis.

RESULTS. Human cell lines PC-3M, PC-3, DU-145, PrEC-1, and MCF10A demonstrated the presence of galectin-3. Galectin-3 was not detected in TSU-pr1 and LNCaP by Western blot analysis. We furthered our studies by examining a series of human prostate tissue samples for expression of galectin-3. Overall, approximately 60–70% of the normal tissue examined demonstrated heterogenous expression of galectin-3. In stage II tumors, however, there was a dramatic decrease in galectin-3 expression in both PIN and tumor sections, with only 10.5% (2/19) of these samples expressing this protein. Stage III tumors also demonstrated a decreased expression of galectin-3, although this downregulation was not as dramatic, with 35% of PIN samples and 52% of tumor tissue expressing galectin-3 ($P < 0.01$).

CONCLUSIONS. These data demonstrate that galectin-3 is downregulated in prostate cancer. The altered downregulation pattern of galectin-3 observed between tumor stages suggests different roles for galectin-3 in the progression of prostate cancer. Prostate 44:118–123, 2000.

© 2000 Wiley-Liss, Inc.

KEY WORDS: prostate neoplasms; lectin; adhesion molecules

INTRODUCTION

The most devastating aspect of cancer is the ability of tumor cells to disseminate from their primary site to distant organ metastases. Cancer-related deaths are most often the result of metastatic disease, rather than the primary tumor. Carcinoma of the prostate is the second leading cause of cancer-related deaths in males in the United States. Projected estimates for 1999 indicate that there will be approximately 179,300 newly diagnosed prostate cancers, and that 37,000 men will die from this disease [1]. More than half the number of patients with prostate cancer already have metastases at the time of diagnosis of their disease. Although there has been much advancement and success in the treatment of localized tumors, little has been found in the way of treatment and prevention of metastatic cancer.

For a cancer cell to successfully leave the primary tumor and establish itself in a new organ site requires a complex cascade of events [2]. It involves the inva-
sion of the primary tumor into the vasculature, the release of tumor cells or tumor embolii into the circulation, the arrest of these cells in distant organs, and finally the development of these tumor cells into secondary neoplasms. If a tumor fails at any one of these steps, metastasis does not occur.

One of the key steps in metastasis is the interaction between the surface adhesion molecules on tumor embolii and receptor molecules on target organ endothelium [3–6]. These surface adhesion molecules belong to several families of proteins including the integrin, cadherin, immunoglobin, laminin, and lectin families. Galectin-3 (gal-3) is part of a growing family of carbohydrate-binding proteins that fulfill two criteria: 1) affinity for β-galactosides; and 2) significant sequence homology in the carbohydrate binding site [7]. Gal-3, previously known as CBP-35, Mac-2, L-29, L-34, and L-31, has a monomer Mr of approximately 30,000 and consists of two distinct structural domains: an amino-terminal domain containing a repetitive sequence rich in leucine, tyrosine, and proline residues, and a carboxyl terminal domain with a globular structure encompassing the carbohydrate binding site [7–14]. Gal-3, through its interaction with specific ligands, is involved in multiple biological processes, including cell growth, differentiation, inflammation, transformation, metastasis, and adhesion [7–14]. Although the precise role of gal-3 remains to be determined, several studies have demonstrated that gal-3 is upregulated in a variety of human cancers. For example, gal-3 expression was significantly higher in invasive colon cancers as compared to colonic epithelium [15]. Studies have also demonstrated that metastatic tissue expressed higher levels of gal-3 than primary cancers [15]. Expression of gal-3 was upregulated in malignant thyroid neoplasms as compared to thyroid adenomas or normal thyroid tissue, as well as tumors of the central nervous system [16–18]. Alternatively, it has been postulated that gal-3 functions to bind cells to laminin in the extracellular matrix, and loss of this expression correlates with acquisition of an invasive phenotype. Studies in endometrial, colon, and breast cancers demonstrate decreased gal-3 expression as compared to normal cells [19–21]. We previously reported that galectin-3 expression is found in prostate cancer cells, and we postulated that gal-3 was involved in the progression of prostate cancer [22]. The purpose of this study was to examine galectin-3 expression in normal prostate tissue, prostate cancer tissue, and human prostate cancer cell lines.

**MATERIALS AND METHODS**

**Antibody Production**

A polyclonal antibody to galectin-3 was previously described [23]. Briefly, the galectin-3 gene was isolated from the HT1080 human fibrosarcoma cDNA library (lambda gt11 phage, Clontech, Palo Alto, CA), sequenced, and transferred to the EcoRI site of the bacterial expression vector, pET5b (Promega, Madison, WI). Then, the protein product was extracted from the bacteria cells, put over an asialofetuin column, and eluted with lactose. The eluant was dialysed against water and lyophilized. Afterward, the lyophilized protein was sent to Zymed (San Francisco, CA) for antibody production in rabbits.

**Cell Culture**

The MCF10A breast epithelial cell line was maintained in Dulbecco’s modified Eagle’s medium (DMEM) and F-12 nutrient mixture (1:1; Gibco/BRL, Gaithersburg, MD) supplemented with the following: 5% equine serum (Gibco/BRL), 1% antibiotic-antimycotic solution (Sigma, St. Louis, MO), insulin (10 µg/ml; Sigma), cortisol (1.4 × 10−6 M; Sigma), cholera enterotoxin (100 ng/ml; ICN Biomedicals, Cleveland, OH), and epidermal growth factor (20 ng/ml; Gibco/BRL) [24]. The human prostate epithelial cell line, PrEC-I, was obtained from Clonetics (San Diego, CA) and immortalized in our laboratory, using the SV-40 large T antigen as previously described [25]. This cell line was maintained in DMEM supplemented with 10% fetal bovine serum (FBS; Gibco/BRL) and 1% antibiotic-antimycotic solution. The prostate cell line TSU-PR1 was obtained from J. Isaacs (Johns Hopkins, Baltimore, MD) [26]. The human prostate cancer cell lines PC3, DU145, and LNCaP were obtained from the American Type Culture Collection (ATCC, Rockville, MD) [27–30]. The human prostate cancer cell line PC3 Bone, which metastasizes preferentially to bone tissue, was obtained from Mark Stearns, Ph.D (University of Pennsylvania) [31]. TSU-PR1, DU-145, PC3 Bone, PC3, and LNCaP were maintained in RPMI-1640 media containing 10% FBS and 1% antibiotic-antimycotic solution.

**Western Blot Analysis**

Aliquots of whole-cell lysates were resolved by electrophoresis on a 10% SDS-polyacrylamide gel, using standard procedures. After electrophoresis, the gels were submerged in transfer buffer (192 mM glycine and 0.25 mM Trizma base, pH 8.3) and allowed to equilibrate for 30 min. Proteins were then transferred to a Hybond ECL nitrocellulose membrane (Amersham Life Sciences, Buckinghamshire, UK) for 1 hr at 4°C at 100 volts using a BioRad Mini Protean II Transfer Unit (BioRad, Hercules, CA). For Western blotting, the ECL Western Blotting Detection Kit was used (Amersham Life Sciences). The detection system uses a chemiluminescent reagent that is cleaved by horse-
radish peroxidase (tethered to the secondary antibody) and produces a signal easily detected using standard X-ray film. All reagents were obtained from Amersham Life Sciences. After transfer, the membrane was submerged in a 10% milk solution for 1 hr to block any nonspecific binding. The membrane was then washed quickly in PBS with 0.1% Tween 20 (PBST), followed by a 15-min wash in PBST and two 5-min washes in PBST. The membrane was incubated for 1 hr at room temperature with a primary antibody (rabbit anti-human galectin-3: 1 mg/ml in stock solution) at a final concentration of 300 μg/ml and washed as stated above in PBST. The membrane was then incubated for 30 min at room temperature with secondary antibody (sheep anti-rabbit Ig horseradish peroxidase-linked whole antibody, Amersham Life Sciences; 0.125 mg/ml) and washed once in PBST for 15 min, followed by four 5-min washes in PBST. After the final wash, galectin-3 was detected using the ECL kit, following the manufacturer’s instructions. X-ray film was placed over the membrane, and the film was exposed for different time periods for optimum visualization.

Prostate Tissue Immunohistochemistry

A modification of the biotin-avidin complex method was used to determine the distribution of galectin-3 in 39 matched paraffinized normal and prostate cancer tissue samples obtained from the University of Michigan Tissue Procurement Core. All samples had been previously verified by a pathologist (K.J.W.). Samples were first deparaffinized by twice incubating in xylene for 5 min, ethanol for 3 min, and 90% ethanol for 3 min. Afterwards, slides were placed in a 0.01 M PBS solution. Tissue section pairs were incubated in an 8% goat serum solution in 0.01 M PBS for 20 min at room temperature to block nonspecific binding. The blocking solution was then removed, and 0.2 mg/ml of the gal-3 antibody in 0.01 M PBS were added to one of the tissue sections for 2 hr at room temperature. The other tissue section pair was incubated in 0.01 M PBS only to detect any nonspecific binding.

The gal-3 antibody solution was removed and tissue sections were quickly rinsed twice with 0.01 M PBS, and then washed twice for 5 min with 0.01 M PBS. An anti-rabbit biotinylated secondary antibody from the VECTASTAIN Elite Immunodetection Kit (Vector Laboratories, Burlingame, CA) was added to the tissue sections and allowed to incubate for 30 min, followed by two quick washes and two 5-min washes with 0.01 M PBS. Vectastain ABC complexing reagent was then added to each tissue section and allowed to incubate for 30 min, followed by two quick rinses and two 5-min washes with 0.01 M PBS. Immunodetection of galectin-3 on the tissue sections was visualized by using the Vector peroxidase substrate kit (DAB kit). Tissue sections were counterstained with hematoxylin for 2 min, followed by incubation of tissue sections in 95% ethanol for 3 min twice, ethanol for 3 min twice, and xylene for 3 min twice. Coverslips were mounted using Permount (Fisher, Pittsburgh, PA).

Stained specimens were scored by two independent observers on a scale ranging from 0–3, with 0 indicating a lack of stain and 3 indicating the presence of intense staining. Observations took into account the difference in staining between prostate intraepithelial neoplasia (PIN), tumor, normal epithelial, and basal-cell layers.

RESULTS

Expression of Galectin-3 in Prostate Cells

We first examined the pattern of expression of gal-3 in a series of nontumorigenic and tumorigenic prostate cell lines by Western blot analysis (Fig. 1). Lysates extracted from each cell line demonstrated the presence of a 29,000-kDa protein in the following cell lines: MCF10A, PrEC-1, DU-145, LNCaP, PC-3, and PC-3M (PC3 Bone). Despite numerous attempts, TSU-PR1 and LnCAP cell lines did not demonstrate gal-3 expression (Fig. 1). There appears to be no significant difference in
Staining in tumors did not correlate with Gleason subpopulations of cells were staining differently. Staining was often focal and intense in tumors, suggesting that tumors stained positive (gal-3) while 52% (10/19) of stage III tumors demonstrated gal-3 staining, while 35% (7/20) of stage II tumors demonstrated gal-3 staining, and 10.5% (2/19) of stage II tumors demonstrated strong expression of galectin-3, 6/19 demonstrating moderate expression, and 1/19 demonstrated strong expression of gal-3 throughout the sample. In patients with stage III disease, epithelial cells and basal cells stained positive for galectin-3, 6/19 demonstrating moderate expression of galectin-3, although this decrease was not as dramatic, with 35% of PIN samples expressing this protein. Positive expression in both PIN and tumor sections, with only 10% of these samples expressing this protein. Positive expression was often focal and intense in tumors, suggesting that subpopulations of the cells were staining differently. Staining in tumors did not correlate with Gleason grade. Atrophic cells in all specimens stained intensely.

**DISCUSSION**

It has been demonstrated that gal-3 has a variety of functions in the cell, ranging from binding to the nuclear matrix to acting as a substrate for matrix metalloproteinases. On the cell surface, gal-3 has been demonstrated to bind laminin in the extracellular matrix. Previous reports are contradictory, suggesting that gal-3 may be upregulated or downregulated as a cell requires a tumorigenic phenotype. Some reports suggest that downregulation of gal-3 in conjunction with dissolution of the basement membrane through upregulation of metalloproteinases would allow tumor cells to disseminate. Conversely, upregulation of gal-3 in metastatic cells could allow greater adhesion to target organ endothelial cells. In the present study, we examined several prostate cell lines as well as human prostate tissue to determine the galectin-3 expression pattern in these samples. All cell lines, with the exception of TSU-PR1 and LnCaP, demonstrated gal-3 expression by Western blot analysis. Western blot analysis failed to demonstrate the presence of galectin-3 in both LnCaP and TSU-PR1 cultures. These results are consistent with recently reported results examining expression of galectin-3 in human prostate cell lines [32]. No change in vitro expression of galectin-3 was observed by Western blot analysis of lysates between the nontumorigenic line PREC-1 and the tumorigenic lines examined.

Examination of the expression of galectin-3 in human prostate tissue, however, yielded interesting results. Prostate tissue samples from 39 patients containing a tumor tissue sample and matched control samples were stained for galectin-3 expression. Overall, approximately 60–70% of the normal tissue examined demonstrated heterogenous expression of galectin-3. It is conceivable that this heterogenous expression of galectin-3 in normal tissue could be influenced by proximal tumor tissue. However, this notion was not further explored in this study. In stage II tumors, there was a dramatic decrease in galectin-3 expression in both PIN and tumor sections, with only 10% of these samples expressing this protein. Positive staining was often focal and intense in tumors, suggesting that subpopulations of the cells were staining differently. Stage III tumors also demonstrated a decreased expression of galectin-3, although this decrease was not as dramatic, with 35% of PIN samples and 50% of tumor tissue expressing galectin-3.

**CONCLUSIONS**

These observations are consistent with previous reports demonstrating a decrease in galectin-3 expres-
sion in endometrial, breast, and ovarian cancers [19,20,33]. Although this is controversial, other investigations have shown an increase in galectin-3 in malignant progression [15,21]. Other reports also demonstrate that increased expression of galectin-3 is associated with high metastatic potential [15–18]. Our results, combined with those previously reported, suggest that the role of galectin-3 in tumorigenesis may be dependent on cell type. Furthermore, our data support the notion that galectin-3 may play a different role in tumor progression depending on tumor stage. Our data do not clearly indicate that a dramatic decrease is observed in tumors of all stages, as those of higher stage demonstrated only slight, albeit statistically significant ($P < 0.01$) decreased expression. This phenomenon may also explain the lack of expression of galectin-3 observed in LnCaP and TSU-Prl cultures. Alternatively, this lack of expression in LnCaP and TSU-Pr1 cultures or the expression of galectin-3 in the other cell lines examined could be attributed to cultural artifacts. Further studies are warranted to examine the expression pattern of galectin-3 in more tumor specimens to determine the role of galectin-3 expression in prostate cancer progression.

Fig. 2. Expression of galectin-3 in human prostate tissue. Samples were subjected to immunohistochemistry, using a polyclonal antibody to galectin-3 as described in Materials and Methods. Pictures were taken at a magnification of ×10. Staining of cells was heterogeneous; examples are given here of (A) basal cells, (B) epithelial cells, (C) atrophic, (D) PIN, (E) focal tumor, and (F) patchy tumor.
ACKNOWLEDGMENTS

We gratefully acknowledge the secretarial assistance of Marty Merris-Davis and Jasmine Bhatia. This work was supported by SPORE grant P50 CA 69568 at the University of Michigan Comprehensive Cancer Center. M.J.P. and C.R.C. are supported by 1997 and 1999 American Foundation for Urological Disease Fellowships sponsored by Dornier Medical Systems, Inc., and Zeneica Pharmaceuticals, respectively.

REFERENCES